At AIS, we believe in facilitating free remote access to excellent surgical contents (synchronous and on-demand) provided by the best international surgeons. This is the starting point to rewrite the rules of training and learning through the use of tools that combine technology and innovation. We believe in democratizing surgical and medical knowledge!
Would you like to be an AIS ambassador in your country?
Write us at info@aischannel.com with the subject line: “I would like to be an AIS ambassador"
.jpg)
Marja Boermeester is professor of surgery and clinical epidemiologist, and passionated DJ (house, techhouse, mainstream). Principal investigator of many multicentre trials on diagnostics and treatment of abdominal infections (e.g. RELAP, OPTIMA, ESCAPE, OPTIMAP, DIABOLO). She received many grants (e.g. 10 ZonMW Health Care & Efficacy Research Grants (Doelmatigheidsonderzoek) and trials were published in international high-ranked publications (NEJM, JAMA, Radiology, BMJ).
Her core business in GI / HPB surgery is intestinal failure surgery (enterocutaneous fistula or short bowel), acute abdominal infections (peritonitis, acute and chronic pancreatitis), surgery of intestinal failure , late-phase abdominal reconstruction after peritonitis, abdominal catastrophes. She has fifteen PhD fellows under her supervision, and 2 post-docs working with her. She is member of the AMC Research Council and Principal Investigator at this institute, member of the writing committee of the Dutch Pancreatitis Study Group (DPSG), principal investigator of the DPSG section Chronic Pancreatitis, and member of several guideline committees (Antibiotics in Sepsis, Acute Diverticulitis, Peri-operative Patient Safety, and Diagnostics of Acute Abdominal Pain).
Also national coordinator Pancreas Pearl at the String of Pearls Initiative (PSI), President of the Surgical Infection Society Europe (SIS-E), steering committee of the WHO Global Guidelines on Surgical Site Infections.
She has founded the SURgical Patient Safety System (SURPASS) checklist, results of which were published in the New England Journal of Medicine in 2010. Several hospitals in Europe have started with SURPASS or equivalent.